Asset Details
Do you wish to reserve the book?
A miRNA signature predicts benefit from addition of hypoxia-modifying therapy to radiation treatment in invasive bladder cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A miRNA signature predicts benefit from addition of hypoxia-modifying therapy to radiation treatment in invasive bladder cancer
Do you wish to request the book?
A miRNA signature predicts benefit from addition of hypoxia-modifying therapy to radiation treatment in invasive bladder cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A miRNA signature predicts benefit from addition of hypoxia-modifying therapy to radiation treatment in invasive bladder cancer
2021
Overview
Background
miRNAs are promising biomarkers in oncology as their small size makes them less susceptible to degradation than mRNA in FFPE tissue. We aimed to derive a hypoxia-associated miRNA signature for bladder cancer.
Methods
Taqman miRNA array cards identified miRNA seed genes induced under hypoxia in bladder cancer cell lines. A signature was derived using feature selection methods in a TCGA BLCA training data set. miRNA expression data were generated for 190 tumours from the BCON Phase 3 trial and used for independent validation.
Results
A 14-miRNA hypoxia signature was derived, which was prognostic for poorer overall survival in the TCGA BLCA cohort (
n
= 403,
p
= 0.001). Univariable analysis showed that the miRNA signature predicted an overall survival benefit from having carbogen–nicotinamide with radiotherapy (HR = 0.30, 95% CI 0.094–0.95,
p
= 0.030) and performed similarly to a 24-gene mRNA signature (HR = 0.47, 95% CI 0.24–0.92,
p
= 0.025). Combining the signatures improved performance (HR = 0.26, 95% CI 0.08–0.82,
p
= 0.014) with borderline significance for an interaction test (
p
= 0.065). The interaction test was significant for local relapse-free survival LRFS (
p
= 0.033).
Conclusion
A 14-miRNA hypoxia signature can be used with an mRNA hypoxia signature to identify bladder cancer patients benefitting most from having carbogen and nicotinamide with radiotherapy.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Biomarkers, Tumor - genetics
/ Biomedical and Life Sciences
/ Cancer
/ Carbon Dioxide - administration & dosage
/ Carbon Dioxide - pharmacology
/ Cell Hypoxia - radiation effects
/ Cell Proliferation - drug effects
/ Cell Proliferation - radiation effects
/ Cell Survival - drug effects
/ Cell Survival - radiation effects
/ Gene Expression Regulation, Neoplastic - drug effects
/ Gene Expression Regulation, Neoplastic - radiation effects
/ Humans
/ Hypoxia
/ miRNA
/ mRNA
/ Niacinamide - administration & dosage
/ Oligonucleotide Array Sequence Analysis
/ Oncology
/ Oxygen - administration & dosage
/ Tumors
